2007 Ann Schreiber Grant Recipient – Mitchell Cheung
Mitchell Cheung, Ph.D.
Fox Chase Cancer Center
Testing New Therapeutic Agents to Treat Ovarian Cancer
Dr. Cheung is researching new types of drugs that are designed to deactivate two molecular pathways, called AKT and PAK, which are believed to make ovarian cancers particularly aggressive. In his project, he will target these two pathways with small molecule inhibitors to test whether administration of two or more of these agents can be more effective than a single agent in ovarian cancer therapy. Initially, he will use cells grown in culture to identify the optimal drug combinations and drug concentrations. Studies in mice will then be used to further evaluate our proposed treatment regimen.
The five-year survival rate for ovarian cancer has increased by only 8% in the last 30 years.
We are at a critical crossroads for supporting research into unlocking the mysteries of ovarian cancer. You can make a difference by supporting the research of the Ovarian Cancer Research Fund.
Help us find a cure for ovarian cancer. Donate online and make a difference.